Pharma Stock In Focus For Posting Strong FY25 Results; Scrip Jumps 5% In Early Trade After FII Returns In Q4

Sudarshan Pharma Industries Limited (SPIL) is expected to draw market attention on Monday after the robust financial and operational results for the two halves of the fiscal year 2025 were disclosed. The rise in share price is SPIL's extraordinary five-year, multibagger claim of over 325% in ROI. Regardless of closing at Rs 26.66 on May 2 and lower by 1.99%, in the last five years, SPIL has surpassed targets by over 325%. On Monday, the stock jumped around 5% in the early trade and touched an intraday high of Rs 27.99 compared to the previous close.

Its consolidated net profit in Q4 FY2025 was Rs 10.03 crore, up more than 50% from Rs 6.60 crore in the same period last year, according to a corporate release. During the reporting quarter, the revenue from operations was Rs 277.26 crore, which was 16.6% more than the Rs 237.74 crore reported in Q4 of FY2024. According to Sudarshan Pharma, its net profit for the entire fiscal year 2025 was Rs 15.95 crore, up from Rs 11.45 crore in the previous year.

SPIL has increased control over domestic and international sales of its manufactured and exported pharmaceuticals. In addition, it is looking to improve profit margins by the resale of some APIs in India.

An important milestone was achieved on November 22, 2024 where SPIL made a stock split and "each fully paid up equity of Rs 10 was turned into 10 shares of Rs 1.

The measure sought to improve liquidity and boost retail investor participation. Foreign Institutional Investors (FIIs) showed further confidence as they purchased 1.29 crore shares in March 2025, increasing their holding stake to 18.45%, a notable rise from the September 2024 figure. Alongside the stock's performance, delivering 358% returns from its 52-week low of Rs 5.82.

SPIL was established in 2008 and has been strong in exporting to the UK and Australia, alongside Uzbekistan, Oman, Syria, Taiwan and parts of MENA. The company also operates through Ratna Lifescience Pvt Ltd, a subsidiary focusing on R&D, with which they have been working since 2017, which gives them more control over their schedule. Additionally, the company holds a 51% stake in Ishwari Healthcare Pvt. Ltd, diversifying claims.

In November 2024, SPIL furthered their innovation plans by signing an MoU with Ardes Laboratories Pvt. Ltd. also modified their terms with Daundi Biological Pvt. Ltd. to a five-year lease to rent an area for a new R&D center that is expected to begin operation by March 2025.

The company has registered 56 of its 96 products under the "R" Trade Mark. Recently, it has launched a new drug delivery mechanism alongside Love Bird "R" branding, which encompassed five unique products. Unit 2, a new manufacturing site positioned in Palghar, has been outfitted with a tank boasting a one-thousand-litre capacity for oral liquid production.

It has received market approvals for 50 products around the world and can produce 2000 litres each shift. This can scale to 6000 litres with two shifts.

The company also offers sustained growth alongside increasing investor interest, further expanding R&D and manufacturing bases, which allows Sudarshan Pharma Industries Ltd. to strengthen its foothold as an emerging mid-cap pharma stock in India's healthcare sector.